Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer

University of Chinese Academy Sciences

Status: Completed

Conditions: Non-small Cell Lung Cancer

Treatments: Other: nonIntervention

Study type: Observational

Funder types: Other

Identifiers

NCT04266691

LN-OMs

Details and patient eligibility

About

Analysis of driver gene variation in early stage non-small cell lung cancer

Full description

Fluorescence quantitative polymerase chain reaction (PCR) was used to detect the variation of driver gene in regional lymph nodes of early stage non-small cell lung cancer (NSCLC), and to analyze the relationship between the variation and disease recurrence and survival prognosis. evaluate the effect of the variation of driving gene in lymph nodes of early stage NSCLC on prognosis, identify the high-risk factors that promote the recurrence and metastasis of early stage tumor. so as to improve the diagnosis and treatment path of lung cancer, provide important pathological basis for the clinical diagnosis and treatment of early stage non-small cell lung cancer, enable patients to receive more accurate treatment, and improve their survival prognosis.

Enrollment: 237 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Female or male, 18 years of age or older
2. Histologically or cytologically proven diagnosis of early stage NSCLC
3. The lesion was completely resected by radical surgery
4. Able to get tumor tissue sample
5. Complete information of clinicopathological , survival, recurrence and metastasis can be obtained through follow-up

Exclusion criteria

1. Combine with other tumor type
2. The investigator judges the situation that may affect the clinical search process and results

Trial design

237 participants in 2 patient groups

Driver gene mutation-positive

Description:

Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation positive.

Treatment:

Other: nonIntervention

Driver gene mutation-negative

Description:

Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation negative.

Treatment:

Other: nonIntervention